Eventide Asset Management ORIC Position
Active8-Fund ConvergenceEventide Asset Management increased their position in ORIC Pharmaceuticals Inc. (ORIC) in Q4 2025, holding $7.8M worth of shares across 952,371 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
ORIC is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ORIC-114 in 167 days (Sep 30, 2026), making the timing of Eventide's position particularly relevant.
Short interest stands at 18.6% of float with 11.8 days to cover, indicating significant bearish positioning against Eventide's long thesis.
About ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
18.6%
11.8 days to cover
Eventide Asset Management ORIC Position History
Frequently Asked Questions
Does Eventide Asset Management own ORIC?
Yes. As of Q4 2025, Eventide Asset Management holds 952,371 shares of ORIC Pharmaceuticals Inc. (ORIC) valued at $7.8M. This data comes from their SEC 13F filing.
How many hedge funds own ORIC?
8 specialist biotech hedge funds currently hold ORIC, including EcoR1 Capital, OrbiMed Advisors, Commodore Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy ORIC?
Eventide Asset Management's position in ORIC was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's ORIC position increasing or decreasing?
Eventide Asset Management increased their ORIC position in the most recent quarter, adding 864 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ORICCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →